RxDoctor Payments Data

Kevin Flynn, MD

Urology · Neenah, WINPI 1891174017

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $56,402 with a category attached, or 88.6%. Boston Scientific accounts for 92.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $51,555 and has fallen 99.2% since, to $429 in 2025. Among urology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,402in general payments, 2019–2025

Across 65 payments — averaging $867.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$52K
  • Intuitive Surgical$3K
  • Sumitomo Pharma America, Inc.$179
  • Urogen Pharma, Inc.$158
  • Ferring Pharmaceuticals Inc.$98
  • Axonics, Inc.$64
  • plus $368 from 12 others

What the payments were for

  • Grants$50,00089%
  • Travel & lodging$8602%
  • Food & beverage$2,2874%
  • Education$3,2556%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,402 in reported general payments places this provider in the 95th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$89,538
Medicare patients
297
Services billed
2,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix39$96,069
MyrbetriqMirabegron41$26,708
GemtesaVibegron19$10,052
Tamsulosin Hcl364$5,577
Finasteride190$2,639
Potassium Citrate ErPotassium Citrate12$1,010
Oxybutynin Chloride ErOxybutynin Chloride97$968
Alfuzosin Hcl ErAlfuzosin Hcl23$425
Solifenacin Succinate12$339
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$281
Testosterone Cypionate14$243
Cephalexin73$178
Ondansetron OdtOndansetron14$112
Oxycodone Hcl59$108
Ciprofloxacin Hcl20$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$179$106,12258 claims
Astellas Pharma US IncMyrbetriq$21$26,70841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 urology providers in Wisconsin.

Other urology in Neenah

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →